Form 4: Crinetics Pharmaceuticals CEO Exercises Stock Options and Reports Beneficial Ownership
SEC Form 4 Filing
Crinetics Pharmaceuticals' CEO, Richard Scott Struthers, exercised stock options and reported changes in his beneficial ownership of company stock.
Summary
- On April 15, 2024, Richard Scott Struthers, the President & CEO and a Director of Crinetics Pharmaceuticals, exercised stock options to acquire 20,000 shares of common stock at a price of $1.91 per share.
- Following this transaction, Struthers directly owns 257,835 shares of common stock.
- Struthers also indirectly owns shares through various family trusts and his spouse, totaling 321,000 shares through family trusts and 1,000 shares through his spouse.
- He also directly owns 81,270 stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of insider transactions. The exercise of options could be seen as a positive sign, but it's a routine event.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings for insights into management's view of the company's prospects.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 04/16/2018 | Initial vesting date for the stock options, with 1/48th of the shares vesting monthly thereafter. |
| 03/16/2028 | Expiration date of the stock options. |
| 04/15/2024 | Date of the transaction: CEO exercised stock options. |
| 04/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.